{"id":"NCT02260986","sponsor":"Regeneron Pharmaceuticals","briefTitle":"Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09","primaryCompletion":"2015-08","completion":"2016-10","firstPosted":"2014-10-09","resultsPosted":"2017-10-17","lastUpdate":"2017-10-17"},"enrollment":740,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Dupilumab","otherNames":["REGN668","SAR231893","Dupixent"]},{"type":"DRUG","name":"Placebo (for Dupilumab)","otherNames":[]},{"type":"OTHER","name":"Topical Corticosteroid (TCS)","otherNames":[]}],"arms":[{"label":"Placebo qw","type":"EXPERIMENTAL"},{"label":"Dupilumab 300 mg q2w","type":"EXPERIMENTAL"},{"label":"Dupilumab 300 mg qw","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study was to demonstrate the efficacy of Dupilumab administered concomitantly with topical corticosteroid (TCS) through Week 16 in adult participants with moderate-to-severe atopic dermatitis (AD) compared to placebo administered concomitantly with TCS.","primaryOutcome":{"measure":"Percentage of Participants With Investigator's Global Assessment (IGA) Score of \"0\" or \"1\" and Reduction From Baseline of â‰¥2 Points at Week 16","timeFrame":"Baseline to Week 16","effectByArm":[{"arm":"Placebo qw","deltaMin":12.4,"sd":null},{"arm":"Dupilumab 300 mg q2w","deltaMin":38.7,"sd":null},{"arm":"Dupilumab 300 mg qw","deltaMin":39.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":148,"countries":["United States","Australia","Canada","Czechia","Hungary","Italy","Japan","Netherlands","New Zealand","Poland","Romania","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["39969783","39588375","36808602","36723913","35636689","34994968","34806137","34142350","34037993","33511576","33453450","33165005","33047298","31564057","31424712","31407311","31066001","28478972"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":315},"commonTop":["Dermatitis atopic","Nasopharyngitis","Injection site reaction","Upper respiratory tract infection","Conjunctivitis allergic"]}}